scholarly journals Seroprevalence of viral hepatitis A, B, C, D and E viruses in the Hormozgan province southern Iran

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Mohammad Amin Behzadi ◽  
Victor Hugo Leyva-Grado ◽  
Mandana Namayandeh ◽  
Atoosa Ziyaeyan ◽  
Roya Feyznezhad ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Viral Hepatitis ◽  
Hepatitis A ◽  
Hepatitis A Virus ◽  
Hepatitis Virus ◽  
Public Health Problem ◽  
Global Public Health ◽  
Hepatitis D ◽  
Hbs Ag ◽  
Viral Hepatitis A

Abstract Background Viral hepatitis is a global public health problem affecting millions of people worldwide, causing thousands of deaths due to acute and persistent infection, cirrhosis, and liver cancer. Providing updated serologic data can improve both surveillance and disease control programs. This study is aimed to determine the seroprevalence of markers for viral hepatitis (A, B, C, D and E) and the epidemiology of such infections in the general population of southern Iran’s Hormozgan province. Methods Between 2016 and 2017, a total of 562 individuals with ages ranging from 1 to 86 years, who visited governmental public laboratories for routine check-ups, were tested for the presence of serological markers to hepatitis virus types A to E using enzyme-linked immunosorbent assays. Results The overall anti-hepatitis A virus (HAV) antibody seroprevalence was 93.2% (524/562). The prevalence of anti-hepatitis E virus (HEV) antibodies was 15.8% (89/562) among which 1.6% (9/562) of the seropositive individuals also had evidence of recent exposure to the virus (IgM positivity). Two and a half percent (14/562) were positive for hepatitis B surface (HBs) antigen, whereas 11.6% (65/562) tested positive for anti-hepatitis B core (HBc) antibodies. Among anti-HBc positive patients, 11% (7/65) had HBs Ag and 5% (3/65) were positive for anti-hepatitis D virus (HDV) antibodies. The prevalence of anti-hepatitis C virus (HCV) antibodies was 0.7% (4/562). The seroprevalence of anti-HAV, HEV IgG, anti-HBc antibodies, and HBs Ag increased with age. Conclusion The present study confirms a high seroprevalence of HAV infection among the examined population and reveals high levels of endemicity for HEV in the region. Planned vaccination policies against HAV should be considered in all parts of Iran. In addition, improvements on public sanitation and hygiene management of drinking water sources for the studied area are recommended.

Viral Hepatitis: 1985 Update

1985 ◽  
Vol 7 (1) ◽  
pp. 3-11
Author(s):  
Saul Krugman
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Viral Hepatitis ◽  
Hepatitis A ◽  
Viral Infections ◽  
Hepatitis A Virus ◽  
Fatal Outcome ◽  
Specific Marker ◽  
Hepatitis D ◽  
B Virus

During the past two decades extraordinary advances in hepatitis research have clarified the etiology and natural history of the disease. At least four types of hepatitis have been identified: A, B, D (delta), and non-A, non-B. Hepatitis A virus (HAV), hepatitis B virus (HBV), and hepatitis D virus (HDV) have been characterized. Serologic tests have been developed to detect the antigens and antibodies associated with these three hepatitis infections. As of the present time, the non-A, non-B viral agents have not been identified. Therefore, non-A, non-B hepatitis is diagnosed by excluding other viral causes of hepatitis, such as hepatitis A virus, hepatitis B virus, Epstein-Barr virus (EBV), cytomegalovirus (CMV), and others. A recent report indicating that non-A, non-B hepatitis may be caused by a retrovirus, if confirmed, may provide a specific marker of this infection. The course of viral hepatitis is variable; it may be an asymptomatic, anteric infection, or it may be an acute illness characterized by fever, malaise, anorexia, nausea, abdominal pain, and jaundice. Most patients recover completely, but occasionally the infection may be complicated by chronic hepatitis, cirrhosis, and, occasionally, by a fulminant fatal outcome. This review will be devoted predominantly to a discussion of the diagnostic and prophylactic aspects of hepatitis A and hepatitis B viral infections.

Hepatotropic viruses (hepatitis A, B, C, D and E) in a rural Brazilian population: prevalence, genotypes, risk factors and vaccination

2019 ◽  
Author(s):  
Karlla A A Caetano ◽  
Fabiana P R Bergamaschi ◽  
Megmar A S Carneiro ◽  
Raquel S Pinheiro ◽  
Lyriane A Araújo ◽  
...  
Keyword(s):  
Risk Factors ◽  
Hepatitis B ◽  
Viral Hepatitis ◽  
Hepatitis A ◽  
Hepatitis B Vaccination ◽  
Hcv Rna ◽  
Hepatitis D ◽  
Central Brazil ◽  
Hbv Vaccination ◽  
Viral Hepatitis A

Abstract Background People living in settlement projects represent an emergent rural population in Brazil. Data on their health is scarce and there are no data on viral hepatitis in this population. This study investigated the epidemiology of viral hepatitis A-E in residents of settlement projects in central Brazil. Methods During 2011 and 2012, 923 people living in rural settlements in central Brazil were interviewed and tested to estimate the prevalence of exposure to viral hepatitis A-E, to identify the circulating hepatitis B virus (HBV)/hepatitis C virus (HCV) genotypes and risk factors for HBV exposure and to evaluate adherence to the hepatitis B vaccination series. Results Overall, 85.9, 3.9, 0.4 and 17.3% of individuals showed evidence of exposure to hepatitis A virus (HAV), hepatitis E virus, HCV and HBV, respectively. Among HBV-DNA positive samples (n=8), subgenotypes A1 (n=3) and A2 (n=1) and genotype D/subgenotype D3 (n=4) were identified. Hepatitis D virus superinfection was detected in 0/16 HBsAg-positive participants. A total of 229 individuals showed serological evidence of HBV vaccination. In total, 442 settlers were eligible for vaccination, but only 150 individuals completed the vaccine series. All anti-HCV-positive samples (n=4) were also HCV-RNA positive and identified as subtype 1a. Conclusions The intermediate endemicity of HAV, the higher prevalence of HBV exposure compared with urban areas and the low compliance with HBV vaccination requires preventive measures focused on rural populations, emphasizing the need for HAV and HBV vaccination.

Salivary and Serum Biochemical Alterations in Patients with Acute Viral Hepatitis

2018 ◽  
Vol 69 (3) ◽  
pp. 747-751 ◽  
Author(s):  
Daniela Gabriela Badita ◽  
Iulia Ioana Stanescu ◽  
Andra Balcangiu Stroescu ◽  
Dan Piperea Sianu ◽  
Daniela Miricescu ◽  
...  
Keyword(s):  
Viral Hepatitis ◽  
Hepatitis A ◽  
Hepatitis A Virus ◽  
World Population ◽  
Major Health Problem ◽  
Major Health ◽  
Biochemical Alterations ◽  
B Virus ◽  
Serum Biochemical ◽  
Viral Hepatitis A

Viral hepatitis represents a major health problem worldwide. Approximately 1.4 million people are infected with hepatitis A virus every year, although given that most of the cases evolve asymptomatically the real number could be even higher. At the same time, hepatitis B virus affects up to 30% of the world population and represents one of the main causes of cirrhosis and hepatocellular carcinoma. Thus, it is very important to understand the physiopathology of viral hepatitis A and B not only for the diagnosis, but also for the therapeutic protocol. The present research aimed to determine if HAV and HBV can alter serum and salivary levels of total protein and of 2 important electrolytes: calcium and potassium.

Viral Hepatitis Other than A, B, or C

2016 ◽  
Author(s):  
Nadeem Anwar ◽  
Kenneth E. Sherman
Keyword(s):  
Hepatitis B ◽  
Viral Hepatitis ◽  
Hepatitis E Virus ◽  
Hepatitis Virus ◽  
Cell Damage ◽  
Hepatitis E ◽  
Hepatitis D ◽  
Hepatitis D Virus ◽  
Treatment And Prevention ◽  
Key Words Hepatitis

Viral hepatitis is a global, although variably distributed, health problem associated with significant morbidity and mortality. Infection with a hepatitis virus leads to acute inflammation and liver cell damage (hepatocyte injury). Such infection may be symptomatic or subclinical and may result in disease resolution, death from fulminant hepatic failure, or development of  a chronic disease state. Whereas the chronic infection with hepatitis B and C accounts for a global burden of more than 500,000,000 cases, the global death rate from all types of hepatitis is approximately 1 million people annually. This review focuses on the virology, epidemiology, clinical features, diagnosis, treatment, and prevention of hepatitis D and hepatitis E, as well as other viruses associated with hepatitis. Figures show the global distribution of hepatitis D infection, elevation of anti–hepatitis D virus antibodies in hepatitis B/hepatitis D virus coinfection, geographic distribution of hepatitis E virus by genotype, factors significant in the pathogenesis of hepatitis E, and pattern of antibody elevation in hepatitis E. The table lists proposed diagnostic criteria for hepatitis E virus. This review contains 5 highly rendered figures, 1 table, and 42 references. Key words: hepatitis D, hepatitis D virus, hepatitis E, hepatitis E virus, non-A hepatitis, non-B hepatitis, non-C hepatitis, viral hepatitis 

Viral Hepatitis Other Than A, B, or C

2016 ◽  
Author(s):  
Nadeem Anwar ◽  
Kenneth E. Sherman
Keyword(s):  
Hepatitis B ◽  
Viral Hepatitis ◽  
Hepatitis E Virus ◽  
Hepatitis Virus ◽  
Cell Damage ◽  
Hepatitis E ◽  
Hepatitis D ◽  
Hepatitis D Virus ◽  
Treatment And Prevention ◽  
Key Words Hepatitis

Viral hepatitis is a global, although variably distributed, health problem associated with significant morbidity and mortality. Infection with a hepatitis virus leads to acute inflammation and liver cell damage (hepatocyte injury). Such infection may be symptomatic or subclinical and may result in disease resolution, death from fulminant hepatic failure, or development of  a chronic disease state. Whereas the chronic infection with hepatitis B and C accounts for a global burden of more than 500,000,000 cases, the global death rate from all types of hepatitis is approximately 1 million people annually. This review focuses on the virology, epidemiology, clinical features, diagnosis, treatment, and prevention of hepatitis D and hepatitis E, as well as other viruses associated with hepatitis. Figures show the global distribution of hepatitis D infection, elevation of anti–hepatitis D virus antibodies in hepatitis B/hepatitis D virus coinfection, geographic distribution of hepatitis E virus by genotype, factors significant in the pathogenesis of hepatitis E, and pattern of antibody elevation in hepatitis E. The table lists proposed diagnostic criteria for hepatitis E virus. This review contains 5 highly rendered figures, 1 table, and 42 references. Key words: hepatitis D, hepatitis D virus, hepatitis E, hepatitis E virus, non-A hepatitis, non-B hepatitis, non-C hepatitis, viral hepatitis 

Viral Hepatitis A: Virus, Disease, and Control

1984 ◽  
pp. 365-376
Author(s):  
F. DEINHARDT ◽  
J. ABB ◽  
V. GAUSS-MüLLER ◽  
K. VON DER HELM ◽  
M. ROGGENDORF ◽  
...  
Keyword(s):  
Viral Hepatitis ◽  
Hepatitis A ◽  
Hepatitis A Virus ◽  
Virus Disease ◽  
Viral Hepatitis A ◽  
And Control

scholarly journals Biochemical Parameters in Common Viral Hepatitis

1970 ◽  
Vol 11 (1) ◽  
pp. 42-45 ◽  
Author(s):  
Md Ashraf-Uz-Zaman ◽  
Bilquis Ara Begum ◽  
Humaira Binte Asad ◽  
Shafia Sharmin Moutoshi ◽  
Md Nasiruddin
Keyword(s):  
Hepatitis C ◽  
Hepatitis B ◽  
Viral Hepatitis ◽  
Biochemical Parameters ◽  
Hepatitis A ◽  
Serum Alkaline Phosphatase ◽  
Hepatitis E ◽  
Mean Value ◽  
Serum Bilirubin Level ◽  
Hepatitis D

Viral hepatitis is the inflammation of the liver caused by hepatitis viruses. The most common causes of viral hepatitis are the five unrelated hepatotropic viruses Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, and Hepatitis E. The aim of this study is to assess the biochemical parameters in viral hepatitis which varies with respect to the different types of viral hepatitis. Sex of the patient affected by Hepatitis A was almost similar in male and female, being 9 (45%) and 11 (55%) in respectively. But in contrast, more than eighty per cent (85%) Hepatitis-E affected population was male. Similar scenario was found in Hepatitis B And C infection (Male- 75%,67%, Female 25,35%). Mean value with standard deviation (±SD) of serum bilirubin level was highest in Hepatitis E (251 ± 125.19 ìmol/l). Value of serum ALT in hepatitis E was found to be 1794 U/l (highest), hepatitis B 1362 U/l hepatitis C are 135.45 U/L,. Serum aspartate aminotransferase (S.AST) is also raised in all types of vira hepatitis but more in Hepatitis E (765 U/l) and Hepatitis B (430 U/l). Serum Alkaline Phosphatase (ALP) was raised significantly in Hepatitis B (240 U/l). The prothombin time was more altered in Hepatitis-E (22.7seconds) and Hepatitis-B (18.5 seconds). There was no significant alteration in serum protein level. So, it can be concluded that derangement of biochemical parameters in patients suffering from common types of viral hepatitis is more in HEV and HBV and comparatively less in HAV and HCV. Keywords: Viral hepatitis, hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E DOI:10.3329/jom.v11i1.4268 J Medicine 2010: 11: 42-45

History and Global Burden of Viral Hepatitis

2016 ◽  
Vol 34 (4) ◽  
pp. 293-302 ◽  
Author(s):  
Hubert E. Blum
Keyword(s):  
Liver Cirrhosis ◽  
Viral Hepatitis ◽  
Hepatitis A ◽  
Hepatitis A Virus ◽  
Hepatitis E ◽  
Chronic Viral Hepatitis ◽  
Global Burden ◽  
Disability Adjusted Life ◽  
Life Years ◽  
Viral Hepatitis A

Between 1963 and 1989, 5 hepatotropic viruses have been discovered that are the major causes of viral hepatitides worldwide: hepatitis A virus, hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis delta virus and hepatitis E virus. Their epidemiology and pathogenesis have been studied in great detail. Furthermore, the structure and genetic organization of their DNA or RNA genome including the viral life cycle have been elucidated and have been successfully translated into important clinical applications, such as the specific diagnosis, therapy and prevention of the associated liver diseases, including liver cirrhosis and hepatocellular carcinoma (HCC). The prevalence of acute and chronic viral hepatitis A-E shows distinct geographic differences. The global burden of disease (prevalence, incidence, death, disability-adjusted life years) has been analyzed in seminal studies that show that the worldwide prevalence of hepatitis A-E has significantly decreased between 1990 and 2013. During the same time, the incidence of HBV-related liver cirrhosis and HCC, respectively, also decreased or increased slightly, the incidence of the HCV-related liver cirrhosis remained stable and the incidence of HCV-related HCC showed a major increase. During the coming years, we expect to improve our ability to prevent and effectively treat viral hepatitis A-E, resulting in the control of these global infections and the elimination of their associated morbidities and mortalities.

scholarly journals THE VIEW OF THE CLINICIAN ON FEATURES OF THE CLINICAL COURSE AND ISSUES OF VACCINAL PREVENTION OF VIRAL HEPATITIS A

2017 ◽  
Vol 20 (1) ◽  
pp. 37-45
Author(s):  
O. A Burgasova ◽  
V. M Volkova ◽  
V. B Tetova ◽  
N. M Belyaeva
Keyword(s):  
Viral Hepatitis ◽  
Old Age ◽  
Hepatitis A ◽  
Hepatitis A Virus ◽  
Clinical Course ◽  
Modern View ◽  
Viral Hepatitis A ◽  
Age Category

The article is devoted to peculiarities of the clinical course of hepatitis A. There is presented the modern view of the immunopathogenesis of hepatitis A virus (HAV) infection. The attention is focused on possibilities of the development of severe, fulminant course especially in patients of the old age category. The authors give the analysis of the main causes of severe fulminant forms of the disease. There are pointed out clinical and laboratory criteria for the assessment of the severity of the course of HAV infection. This article includes information on current aspects of vaccination against HAV, with the indication of the population, especially needed of vaccination

Sign in / Sign up

Export Citation Format

Share Document